Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $77. The company’s shares closed yesterday at $42.10, close to its 52-week low of $40.47.
Yang wrote:
“We note that one or two weeks of data can have a meaningful impact on our total 2018 projections and we used what we believe are conservative assumptions. We believe there could be upside to our current estimate and we believe the risk of Aerie not delivering on its 2018 sales guidance of $20-30 mil is low.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.2% and a 46.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $81.67, which is a 94.0% upside from current levels. In a report issued on November 12, Oppenheimer also initiated coverage with a Buy rating on the stock with a $64 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $40.47. Currently, Aerie Pharma has an average volume of 538.1K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
Read More on AERI:
